Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 12/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 11/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301358 | 0.90 | HSD17B1 (0.49) | HSD17B2HSD17B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL31301411 | 0.87 | POLB (0.45) | HSD17B2HSD17B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL31301359 | 0.86 | MAPT (0.43) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL31301460 | 0.86 | MAPT (0.43) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL31301396 | 0.86 | MAPT (0.46) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL31301314 | 0.86 | TP53 (0.43) | HSD17B2HSD17B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL31301384 | 0.85 | TP53 (0.44) | HSD17B2HSD17B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL31301289 | 0.85 | HSD17B1 (0.44) | HSD17B2HSD17B1MAPTTP53SMN1; SMN2 | |
| SCHEMBL31301336 | 0.81 | GPBAR1 (0.47) | MAPTTP53SMN1; SMN2POLBHPGD | |
| SCHEMBL31301263 | 0.81 | GPBAR1 (0.47) | MAPTTP53SMN1; SMN2POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | HSD17B2 1780/4885HSD17B1 1543/4885MAPT 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.